Aeglea BioTherapeutics
demonstrates durable clinical response at week analysis | Aeglea BioTherapeutics
Company
Deck Type
Sector
Industry
Deck date
June 2020
Slide
10 of 22
Similar slides by Aeglea BioTherapeutics
See diffirences between slides (animation)
Investor Presentation
August 2020
demonstrates durable clinical response at week analysis | Aeglea BioTherapeutics
Related slides by other companies
MindMed
Investor Presentation
December 2024
continued response and remission through week with clinical responder rate and clinical remission rate | MindMed
MindMed
Investor Presentation
November 2024
continued response and remission through week with clinical responder rate and clinical remission rate | MindMed
MindMed
Investor Presentation
January 2025
phase efficacy and durability support gad phase trial plans plans | MindMed
Nuvalent
Investor Presentation
February 2024
activity induced intracranial responses in patients with refractory alk phase refractory complete response alk fusion alk fusion no known resistance mutations lines of therapy including and chemotherapy complete resolution of parietal parenchymal brain metastases after weeks treatment continues at months ongoing mutation weeks resistance alk fusion partial response ongoing confirmed lines of therapy consisting treatment continues at after weeks of and months weeks confirmed courtesy of and hospital vall barcelona courtesy of university united states data as of august central nervous system complete response non small source lin cell lung cancer partial response once daily tyrosine kinase inhibitor | Nuvalent
Other recent decks by Aeglea BioTherapeutics
See all presentations (14 decks)
Investor Presentation
October 2023
Investor Presentation
October 2023
Investor Presentation
September 2023
Investor Presentation
July 2023
Search Thousands of Presentations by World Leading Companies
Trending:
Addressable Market
Ecosystem
Beauty Market
WACC
NFT
Management Team
Investment Highlights